

Frederick L Baehner

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/901100/publications.pdf>

Version: 2024-02-01

65
papers

18,871
citations

87843

38
h-index

114418

63
g-index

66
all docs

66
docs citations

66
times ranked

19353
citing authors

#	ARTICLE	IF	CITATIONS
1	Patient-specific meta-analysis of 12-gene colon cancer recurrence score validation studies for recurrence risk assessment after surgery with or without 5FU and oxaliplatin. <i>Journal of Gastrointestinal Oncology</i> , 2022, 13, 126-136.	0.6	1
2	Endocrine Therapy Response and 21-Gene Expression Assay for Therapy Guidance in HR+/HER2- Early Breast Cancer. <i>Journal of Clinical Oncology</i> , 2022, 40, 2557-2567.	0.8	49
3	A Comparison of Predicted Ipsilateral Tumor Recurrence Risks in Patients With Ductal Carcinoma in Situ of the Breast After Breast-Conserving Surgery by Breast Radiation Oncologists, the Van Nuys Prognostic Index, the Memorial Sloan Kettering Cancer Center DCIS Nomogram, and the 12-Gene DCIS Score Assay. <i>Advances in Radiation Oncology</i> , 2021, 6, 100607.	0.6	9
4	Molecular Drivers of Oncotype DX, Prosigna, EndoPredict, and the Breast Cancer Index: A TransATAC Study. <i>Journal of Clinical Oncology</i> , 2021, 39, 126-135.	0.8	69
5	Association Between 21-Gene Assay Recurrence Score and Locoregional Recurrence Rates in Patients With Node-Positive Breast Cancer. <i>JAMA Oncology</i> , 2020, 6, 505.	3.4	51
6	The run-in phase of the prospective WSG-ADAPT HR+/HER2- trial demonstrates the feasibility of a study design combining static and dynamic biomarker assessments for individualized therapy in early breast cancer. <i>Therapeutic Advances in Medical Oncology</i> , 2020, 12, 175883592097313.	1.4	18
7	Differential impact of prognostic parameters in hormone receptor-positive lobular breast cancer. <i>Cancer</i> , 2020, 126, 4847-4858.	2.0	33
8	Genomic comparison of paired primary breast carcinomas and lymph node macrometastases using the Oncotype DX Breast Recurrence Score [®] test. <i>Breast Cancer Research and Treatment</i> , 2019, 177, 611-618.	1.1	6
9	Accurate Estrogen Receptor Quantification in Patients with Negative and Low-Positive Estrogen-Receptor-Expressing Breast Tumors: Sub-Analyses of Data from Two Clinical Studies. <i>Advances in Therapy</i> , 2019, 36, 828-841.	1.3	10
10	Comparison of the Performance of 6 Prognostic Signatures for Estrogen Receptor-Positive Breast Cancer. <i>JAMA Oncology</i> , 2018, 4, 545.	3.4	246
11	21-Gene Recurrence Score for prognosis and prediction of taxane benefit after adjuvant chemotherapy plus endocrine therapy: results from NSABP B-28/NRG Oncology. <i>Breast Cancer Research and Treatment</i> , 2018, 168, 69-77.	1.1	36
12	21-Gene assay as predictor of chemotherapy benefit in HER2-negative breast cancer. <i>Npj Breast Cancer</i> , 2018, 4, 37.	2.3	65
13	Intrinsic Subtype and Therapeutic Response Among HER2-Positive Breast Tumors from the NCCTG (Alliance) N9831 Trial. <i>Journal of the National Cancer Institute</i> , 2017, 109, djw207.	3.0	26
14	Characterizing the immune microenvironment in high-risk ductal carcinoma in situ of the breast. <i>Breast Cancer Research and Treatment</i> , 2017, 161, 17-28.	1.1	83
15	The analytical validation of the Oncotype DX Recurrence Score assay. <i>Ecancermedalscience</i> , 2016, 10, 675.	0.6	20
16	Breast-cancer-specific mortality in patients treated based on the 21-gene assay: a SEER population-based study. <i>Npj Breast Cancer</i> , 2016, 2, 16017.	2.3	125
17	Prognostic Impact of the Combination of Recurrence Score and Quantitative Estrogen Receptor Expression (<i>ESR1</i>) on Predicting Late Distant Recurrence Risk in Estrogen Receptor-Positive Breast Cancer After 5 Years of Tamoxifen: Results From NRG Oncology/National Surgical Adjuvant Breast and Bowel Project B-28 and B-14. <i>Journal of Clinical Oncology</i> , 2016, 34, 2350-2358.	0.8	71
18	Retrospective analysis of molecular scores for the prediction of distant recurrence according to baseline risk factors. <i>Breast Cancer Research and Treatment</i> , 2016, 159, 71-78.	1.1	11

#	ARTICLE	IF	CITATIONS
19	Association of Stromal Tumor-Infiltrating Lymphocytes With Recurrence-Free Survival in the N9831 Adjuvant Trial in Patients With Early-Stage HER2-Positive Breast Cancer. <i>JAMA Oncology</i> , 2016, 2, 56.	3.4	183
20	A Prospective Comparison of the 21-Gene Recurrence Score and the PAM50-Based Prosigna in Estrogen Receptor-Positive Early-Stage Breast Cancer. <i>Advances in Therapy</i> , 2015, 32, 1237-1247.	1.3	32
21	The relationship between quantitative human epidermal growth factor receptor 2 gene expression by the 21-gene reverse transcriptase polymerase chain reaction assay and adjuvant trastuzumab benefit in Alliance N9831. <i>Breast Cancer Research</i> , 2015, 17, 133.	2.2	21
22	A population-based validation study of the DCIS Score predicting recurrence risk in individuals treated by breast-conserving surgery alone. <i>Breast Cancer Research and Treatment</i> , 2015, 152, 389-398.	1.1	188
23	Surgical Excision Without Radiation for Ductal Carcinoma in Situ of the Breast: 12-Year Results From the ECOG-ACRIN E5194 Study. <i>Journal of Clinical Oncology</i> , 2015, 33, 3938-3944.	0.8	223
24	A 17-gene Assay to Predict Prostate Cancer Aggressiveness in the Context of Gleason Grade Heterogeneity, Tumor Multifocality, and Biopsy Undersampling. <i>European Urology</i> , 2014, 66, 550-560.	0.9	553
25	A Multigene Expression Assay to Predict Local Recurrence Risk for Ductal Carcinoma In Situ of the Breast. <i>Journal of the National Cancer Institute</i> , 2013, 105, 701-710.	3.0	442
26	Lobular Neoplasia of the Breast Revisited With Emphasis on the Role of E-Cadherin Immunohistochemistry. <i>American Journal of Surgical Pathology</i> , 2013, 37, e1-e11.	2.1	137
27	The Prognostic Implications of Macrophages Expressing Proliferating Cell Nuclear Antigen in Breast Cancer Depend on Immune Context. <i>PLoS ONE</i> , 2013, 8, e79114.	1.1	24
28	Accurate Assessment of Human Epidermal Growth Factor Receptor 2. <i>Journal of Clinical Oncology</i> , 2012, 30, 1727-1728.	0.8	3
29	Xenografts faithfully recapitulate breast cancer-specific gene expression patterns of parent primary breast tumors. <i>Breast Cancer Research and Treatment</i> , 2012, 135, 913-922.	1.1	39
30	Elevated Levels of Proliferating and Recently Migrated Tumor-associated Macrophages Confer Increased Aggressiveness and Worse Outcomes in Breast Cancer. <i>Annals of Surgical Oncology</i> , 2012, 19, 3979-3986.	0.7	24
31	The Impact of Primary Melanoma Thickness and Microscopic Tumor Burden in Sentinel Lymph Nodes on Melanoma Patient Survival. <i>Annals of Surgical Oncology</i> , 2012, 19, 1034-1042.	0.7	14
32	MR Imaging Features of Gadofluorine-Labeled Matrix-Associated Stem Cell Implants in Cartilage Defects. <i>PLoS ONE</i> , 2012, 7, e49971.	1.1	10
33	Prognostic value of biologic subtype and the 21-gene recurrence score relative to local recurrence after breast conservation treatment with radiation for early stage breast carcinoma: results from the Eastern Cooperative Oncology Group E2197 study. <i>Breast Cancer Research and Treatment</i> , 2012, 134, 683-692.	1.1	69
34	Molecular-based Testing in Breast Disease for Therapeutic Decisions. , 2012, , 173-188.		1
35	Basal-like and triple-negative breast cancers: a critical review with an emphasis on the implications for pathologists and oncologists. <i>Modern Pathology</i> , 2011, 24, 157-167.	2.9	545
36	Proliferating macrophages associated with high grade, hormone receptor negative breast cancer and poor clinical outcome. <i>Breast Cancer Research and Treatment</i> , 2011, 128, 703-711.	1.1	223

#	ARTICLE	IF	CITATIONS
37	Biologic markers determine both the risk and the timing of recurrence in breast cancer. <i>Breast Cancer Research and Treatment</i> , 2011, 129, 607-616.	1.1	89
38	Elevated PCNA+ tumor-associated macrophages in breast cancer are associated with early recurrence and non-Caucasian ethnicity. <i>Breast Cancer Research and Treatment</i> , 2011, 130, 635-644.	1.1	44
39	Genomic signatures of cancer: Basis for individualized risk assessment, selective staging and therapy. <i>Journal of Surgical Oncology</i> , 2011, 103, 563-573.	0.8	32
40	Estrogen Receptor (<i>ESR1</i>) mRNA Expression and Benefit From Tamoxifen in the Treatment and Prevention of Estrogen Receptor-Positive Breast Cancer. <i>Journal of Clinical Oncology</i> , 2011, 29, 4160-4167.	0.8	120
41	Relationship between Quantitative <i>GRB7</i> RNA Expression and Recurrence after Adjuvant Anthracycline Chemotherapy in Triple-Negative Breast Cancer. <i>Clinical Cancer Research</i> , 2011, 17, 7194-7203.	3.2	20
42	Fluvastatin reduces proliferation and increases apoptosis in women with high grade breast cancer. <i>Breast Cancer Research and Treatment</i> , 2010, 119, 137-144.	1.1	179
43	Relationship Between Tumor Gene Expression and Recurrence in Four Independent Studies of Patients With Stage II/III Colon Cancer Treated With Surgery Alone or Surgery Plus Adjuvant Fluorouracil Plus Leucovorin. <i>Journal of Clinical Oncology</i> , 2010, 28, 3937-3944.	0.8	271
44	Human Epidermal Growth Factor Receptor 2 Assessment in a Case-Control Study: Comparison of Fluorescence In Situ Hybridization and Quantitative Reverse Transcription Polymerase Chain Reaction Performed by Central Laboratories. <i>Journal of Clinical Oncology</i> , 2010, 28, 4300-4306.	0.8	113
45	Prediction of Risk of Distant Recurrence Using the 21-Gene Recurrence Score in Node-Negative and Node-Positive Postmenopausal Patients With Breast Cancer Treated With Anastrozole or Tamoxifen: A TransATAC Study. <i>Journal of Clinical Oncology</i> , 2010, 28, 1829-1834.	0.8	647
46	Molecular Predictors of 3D Morphogenesis by Breast Cancer Cell Lines in 3D Culture. <i>PLoS Computational Biology</i> , 2010, 6, e1000684.	1.5	77
47	Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial. <i>Lancet Oncology</i> , The, 2010, 11, 55-65.	5.1	1,252
48	Phosphorylation of the src Epithelial Substrate Trask Is Tightly Regulated in Normal Epithelia but Widespread in Many Human Epithelial Cancers. <i>Clinical Cancer Research</i> , 2009, 15, 2311-2322.	3.2	46
49	Reply to J.M. Guinebretiere and L. Arnould et al. <i>Journal of Clinical Oncology</i> , 2009, 27, 2734-2735.	0.8	1
50	A Multimarker Prognostic Assay for Primary Cutaneous Melanoma. <i>Clinical Cancer Research</i> , 2009, 15, 6987-6992.	3.2	80
51	Relationship between Topoisomerase 2A RNA Expression and Recurrence after Adjuvant Chemotherapy for Breast Cancer. <i>Clinical Cancer Research</i> , 2009, 15, 7693-7700.	3.2	23
52	The Transmembrane src Substrate Trask Is an Epithelial Protein that Signals during Anchorage Deprivation. <i>American Journal of Pathology</i> , 2009, 174, 1756-1765.	1.9	39
53	Gene expression patterns in formalin-fixed, paraffin-embedded core biopsies predict docetaxel chemosensitivity in breast cancer patients. <i>Breast Cancer Research and Treatment</i> , 2008, 108, 233-240.	1.1	123
54	Estrogen- and Progesterone-Receptor Status in ECOG 2197: Comparison of Immunohistochemistry by Local and Central Laboratories and Quantitative Reverse Transcription Polymerase Chain Reaction by Central Laboratory. <i>Journal of Clinical Oncology</i> , 2008, 26, 2473-2481.	0.8	212

#	ARTICLE	IF	CITATIONS
55	Gene Expression and Benefit of Chemotherapy in Women With Node-Negative, Estrogen Receptor-Positive Breast Cancer. <i>Journal of Clinical Oncology</i> , 2006, 24, 3726-3734.	0.8	2,369
56	Î²1 Integrin Inhibitory Antibody Induces Apoptosis of Breast Cancer Cells, Inhibits Growth, and Distinguishes Malignant from Normal Phenotype in Three Dimensional Cultures and In vivo. <i>Cancer Research</i> , 2006, 66, 1526-1535.	0.4	303
57	Fine Needle Aspiration Cytology of Adult Perineal Rhabdomyosarcoma. <i>Acta Cytologica</i> , 2006, 50, 88-92.	0.7	5
58	A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. <i>Cancer Cell</i> , 2006, 10, 515-527.	7.7	2,729
59	Genes and pathways downstream of telomerase in melanoma metastasis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2006, 103, 11306-11311.	3.3	121
60	Breast Cancer Growth Prevention by Statins. <i>Cancer Research</i> , 2006, 66, 8707-8714.	0.4	309
61	Metastatic Balloon Cell Melanoma. <i>Acta Cytologica</i> , 2005, 49, 543-548.	0.7	22
62	Bladder Cancer Outcome and Subtype Classification by Gene Expression. <i>Clinical Cancer Research</i> , 2005, 11, 4044-4055.	3.2	303
63	A Multigene Assay to Predict Recurrence of Tamoxifen-Treated, Node-Negative Breast Cancer. <i>New England Journal of Medicine</i> , 2004, 351, 2817-2826.	13.9	5,646
64	Fine Needle Aspiration Cytology of Intraoral Epithelioid Hemangioma. <i>Acta Cytologica</i> , 2003, 47, 275-280.	0.7	16
65	Fetal neurenteric cyst causing hydrops: case report and review of the literature. , 1999, 19, 118-121.		18